Advanced search
1 file | 367.81 KB

The cell cycle biomarkers: promising research, but do not oversell them

Norbert Lameire (UGent) , Jill Vanmassenhove (UGent) , Wim Van Biesen (UGent) and Raymond Vanholder (UGent)
(2016) CLINICAL KIDNEY JOURNAL. 9(3). p.353-358
Author
Organization
Abstract
This review focuses on the most recent scientific and clinical information on the development and clinical applicability of the cell cycle biomarkers TIMP-2 and IGFBP-7 in the diagnosis and prognosis of patients at risk for and suffering from acute kidney injury (AKI). A number of evaluation studies have demonstrated that compared with existing biomarkers, urinary excretion of the product of both biomarkers, [TIMP-2]•[IGFBP-7], improved diagnostic performance in assessing the risk for AKI, predicting the need for renal replacement therapy, AKI-related complications and short- and long-term prognoses. The reference intervals for these biomarkers, measured by the recently approved NephroCheck test, have been determined in apparently healthy adults and those with stable chronic morbid conditions without AKI. This review recognizes that the combination of these two cell cycle arrest markers for the early detection of AKI is promising but concludes that its clinical impact is still unproved. Clinicians should understand the utility and limitations of this test before deciding whether to make it available at their institution.
Keywords
glomerulosclerosis, prognosis, creatinine, AKI, biomarkers

Downloads

  • the cell cycle.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 367.81 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Lameire, Norbert, JILL VANMASSENHOVE, Wim Van Biesen, and Raymond Vanholder. 2016. “The Cell Cycle Biomarkers: Promising Research, but Do Not Oversell Them.” Clinical Kidney Journal 9 (3): 353–358.
APA
Lameire, N., VANMASSENHOVE, J., Van Biesen, W., & Vanholder, R. (2016). The cell cycle biomarkers: promising research, but do not oversell them. CLINICAL KIDNEY JOURNAL, 9(3), 353–358.
Vancouver
1.
Lameire N, VANMASSENHOVE J, Van Biesen W, Vanholder R. The cell cycle biomarkers: promising research, but do not oversell them. CLINICAL KIDNEY JOURNAL. 2016;9(3):353–8.
MLA
Lameire, Norbert, JILL VANMASSENHOVE, Wim Van Biesen, et al. “The Cell Cycle Biomarkers: Promising Research, but Do Not Oversell Them.” CLINICAL KIDNEY JOURNAL 9.3 (2016): 353–358. Print.
@article{8086166,
  abstract     = {This review focuses on the most recent scientific and clinical information on the development and clinical applicability of the cell cycle biomarkers TIMP-2 and IGFBP-7 in the diagnosis and prognosis of patients at risk for and suffering from acute kidney injury (AKI). A number of evaluation studies have demonstrated that compared with existing biomarkers, urinary excretion of the product of both biomarkers, [TIMP-2]{\textbullet}[IGFBP-7], improved diagnostic performance in assessing the risk for AKI, predicting the need for renal replacement therapy, AKI-related complications and short- and long-term prognoses. The reference intervals for these biomarkers, measured by the recently approved NephroCheck test, have been determined in apparently healthy adults and those with stable chronic morbid conditions without AKI. This review recognizes that the combination of these two cell cycle arrest markers for the early detection of AKI is promising but concludes that its clinical impact is still unproved. Clinicians should understand the utility and limitations of this test before deciding whether to make it available at their institution.},
  author       = {Lameire, Norbert and Vanmassenhove, Jill and Van Biesen, Wim and Vanholder, Raymond},
  issn         = {2048-8505},
  journal      = {CLINICAL KIDNEY JOURNAL},
  language     = {eng},
  number       = {3},
  pages        = {353--358},
  title        = {The cell cycle biomarkers: promising research, but do not oversell them},
  url          = {http://dx.doi.org/10.1093/ckj/sfw033},
  volume       = {9},
  year         = {2016},
}

Altmetric
View in Altmetric